101 related articles for article (PubMed ID: 10620464)
41. Good manners for the pharmaceutical industry.
Gore M; A'Hern R; Swenerton K
Lancet; 1997 Aug; 350(9074):370. PubMed ID: 9251668
[No Abstract] [Full Text] [Related]
42. ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.
Wheatley K; Gray R
Lancet; 2003 Oct; 362(9392):1333; author reply 1334. PubMed ID: 14575997
[No Abstract] [Full Text] [Related]
43. Good manners for the pharmaceutical industry.
Perren T
Lancet; 1997 Aug; 350(9074):370-1. PubMed ID: 9251669
[No Abstract] [Full Text] [Related]
44. Paclitaxel as a component of initial chemotherapy of advanced ovarian cancer: is the controversy resolved.
Markman M
J Cancer Res Clin Oncol; 1998 Jan; 124(1):1-3. PubMed ID: 9498827
[No Abstract] [Full Text] [Related]
45. [Current status and trends in chemotherapy of ovarian cancer].
Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):67-70. PubMed ID: 8758795
[No Abstract] [Full Text] [Related]
46. Back to the future: multiagent chemotherapy in ovarian cancer revisited.
Cannistra SA
J Clin Oncol; 1999 Mar; 17(3):741-3. PubMed ID: 10071260
[No Abstract] [Full Text] [Related]
47. No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
Vach W; Bergmann TK; Brøsen K
J Clin Oncol; 2008 Apr; 26(11):1903-4; author reply 1904-5. PubMed ID: 18398158
[No Abstract] [Full Text] [Related]
48. Clinical trials referral resource. Ovarian cancer.
Cheson BD
Oncology (Williston Park); 1990 Aug; 4(8):69-75. PubMed ID: 2145013
[No Abstract] [Full Text] [Related]
49. ICON3 and chemotherapy for ovarian cancer.
Pilotti S; Oggionni M; Böhm S; Pierotti MA; Zunino F
Lancet; 2002 Dec 21-28; 360(9350):2087-8; author reply 2088. PubMed ID: 12504454
[No Abstract] [Full Text] [Related]
50. Good manners for the pharmaceutical industry.
Calvert H; Kaye S; Osborne R; Sikora K; Thomas H
Lancet; 1997 Aug; 350(9074):371. PubMed ID: 9251671
[No Abstract] [Full Text] [Related]
51. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.
Kampan NC; Madondo MT; McNally OM; Quinn M; Plebanski M
Biomed Res Int; 2015; 2015():413076. PubMed ID: 26137480
[TBL] [Abstract][Full Text] [Related]
52. Dose-intensity in ovarian carcinoma: hold, enough?
Thigpen JT
J Clin Oncol; 1997 Apr; 15(4):1291-3. PubMed ID: 9193319
[No Abstract] [Full Text] [Related]
53. Confirmation of the "old" standard of care for ovarian cancer and a challenge.
McGuire WP
J Natl Cancer Inst; 2000 May; 92(9):674-5. PubMed ID: 10793094
[No Abstract] [Full Text] [Related]
54. The treatment of ovarian cancer has reached new standards of care.
ten Bokkel Huinink WW
Eur J Cancer; 2000 Jan; 36(1):7-9. PubMed ID: 10741289
[No Abstract] [Full Text] [Related]
55. Response surface methodology and the design of clinical trials for the evaluation of cancer chemotherapy.
Carter WH
Cancer Treat Rep; 1985 Oct; 69(10):1049-53. PubMed ID: 4042084
[No Abstract] [Full Text] [Related]
56. The European Canadian Intergroup trial (OV10 trial) and the US Gynaecologic Oncology Group trial (GOG 111).
Swart AM; Parmar MK; Harper P; Colombo N; Torri V
Int J Gynecol Cancer; 2004; 14(4):697; author reply 698. PubMed ID: 15304171
[No Abstract] [Full Text] [Related]
57. Tide is turning on inequality of care.
Mossman J
Nurs Stand; 1998 May 27-Jun 2; 12(36):14-5. PubMed ID: 9732602
[No Abstract] [Full Text] [Related]
58. Paclitaxel in the management of ovarian cancer: what we know and what we have yet to learn.
Markman M
J Cancer Res Clin Oncol; 1996; 122(2):71-3. PubMed ID: 8576282
[No Abstract] [Full Text] [Related]
59. [Effect of chemotherapy on cytosol proteins of ovarian tumors].
Blumenberg AG; Mavletova DA; Deberer LIu; Gorbachëva LB
Vopr Onkol; 2003; 49(2):162-4. PubMed ID: 12785197
[TBL] [Abstract][Full Text] [Related]
60. Investigational therapies for epithelial ovarian cancer.
Kavanagh JJ
Clin Obstet Gynecol; 1985 Dec; 28(4):846-52. PubMed ID: 4075634
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
